Napsin A is a specific marker for ovarian clear cell adenocarcinoma

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 111-117

  Yamashita, Yoriko ^a,b   Nagasaka, Tetsuro ^b   Naiki Ito, Aya ^a   Sato, Shinya ^a   Suzuki, Shugo ^a   Toyokuni, Shinya ^b   Ito, Masafumi ^c   Takahashi, Satoru ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Clear cell adenofibroma; immunohistochemistry; napsin A; ovarian clear cell adenocarcinoma

Indexed keywords

NAPSIN A; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN;

ADENOCARCINOMA; ADENOFIBROMA; ADENOMA; ADULT; AGED; ARTICLE; CELL SURFACE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIUM; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MUCINOUS ADENOCARCINOMA; MUCINOUS ADENOMA; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; SEROUS ADENOCARCINOMA; SEROUS ADENOMA; SQUAMOUS EPITHELIUM; UTERINE ENDOCERVIX; UTERINE TUBE; YOLK SAC TUMOR; ADENOCARCINOMA, CLEAR CELL; BIOSYNTHESIS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ASPARTIC ACID ENDOPEPTIDASES; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84920700899     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.61     Document Type: Article

References (49)

1. Tatnell PJ, Powell DJ, Hill J, et al. Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett 1998;441:43-48.
2. Chuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999;462:129-134.
3. Schauer-Vukasinovic V, Bur D, Kling D, et al. Human napsin A: expression, immunochemical detection, and tissue localization. FEBS Lett 1999;462:135-139.
4. Hirano T, Auer G, Maeda M, et al. Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res 2000;91:1015-1021.
5. Brasch F, Ochs M, Kahne T, et al. Involvement of napsin A in the C-and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem 2003;278:49006-49014.
6. Ueno T, Linder S, Na CL, et al. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem 2004;279:16178-16184.
7. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003;88:1229-1233.
8. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003;41:155-162.
9. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
10. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol 2011;19:313-317.
11. Zhang P, Han YP, Huang L, et al. Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. Oncol Lett 2010;1: 899-903.
12. Whithaus K, Fukuoka J, Prihoda TJ, et al. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med 2012;136:155-162.
13. Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012;61:1017-1025.
14. Mori K, Kon Y, Konno A, et al. Cellular distribution of napsin (kidney-derived aspartic protease-like protein, KAP) mRNA in the kidney, lung and lymphatic organs of adult and developing mice. Arch Histol Cytol 2001;64:319-327.
15. Mori K, Shimizu H, Konno A, et al. Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules. Arch Histol Cytol 2002;65:359-368.
16. Bishop JA, Sharma R, Illei PB, et al. and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20-25.
17. Chernock RD, El-Mofty SK, Becker N, et al. Napsin a expression in anaplastic, poorly differentiated, and micropapillary pattern thyroid carcinomas. Am J Surg Pathol 2013;37:1215-1222.
18. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349.
19. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13: 385-394.
20. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40.
21. Yamashita Y, Akatsuka S, Shinjo K, et al. Met is the most frequently amplified gene in endometriosisassociated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PloS One 2013; 8:e57724.
22. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary- A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589.
23. Penson RT, Dizon DS, Birrer MJ. Clear cell cancer of the ovary. Curr Opin Oncol 2013;25:553-557.
24. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obst Gynecol 2002;100:281-287.
25. Sangoi AR, Soslow RA, Teng NN, et al. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol 2008;32:269-274.
26. DeLair D, Oliva E, Kobel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 2011;35:36-44.
27. Ohishi Y, Oda Y, Kurihara S, et al. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms. Hum Pathol 2009;40: 1168-1175.
28. Silva EG, Young R. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol 2007;31: 1203-1208.
29. Ballotta MR, Bianchini E, Borghi L, et al. Clear cell carcinoma simulating the 'endometrioid-like variant' of yolk sac tumor. Pathologica 1995;87:87-90.
30. Cetin A, Bahat Z, Cilesiz P, et al. Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report. Eur J Gynaecol Oncol 2007;28:241-244.
31. Takahashi YMH, Hamada S, Urasaki K, et al. Alphafetoprotein producing ovarian clear cell carcinoma with a neometaplasia to hepatoid carcinoma arising from endometriosis: a case report. J Obstet Gynaecol Res 2011;37:1842-1846.
32. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163: 2503-2512.
33. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006;19:83-89.
34. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol 2012;20:580-587.
35. Miao Y, Cai B, Liu L, et al. Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19:1545-1549.
36. Toyama A, Suzuki A, Shimada T, et al. Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci 2012;103: 747-755.
37. Li B, Jin H, Yu Y, et al. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer 2009;19:1347-1352.
38. Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009;22:824-832.
39. Choi CH, Sung CO, Kim HJ, et al. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol 2013;44:1017-1023.
40. Umezu T, Shibata K, Kajiyama H, et al. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J Clin Pathol 2010;63:962-966.
41. Kandalaft PIL, Gown AM. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary. Mod Pathol 2012;25:279A.
42. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin a in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol 2014;38:189-196.
43. Lee JG, Kim S, Shim HS. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer 2012;77:156-161.
44. Rossi G, Cadioli A, Mengoli MC, et al. Napsin A expression in pulmonary sclerosing haemangioma. Histopathology 2012;60:361-363.
45. Schmidt LA, Myers JL, McHugh JB. Napsin A is differentially expressed in sclerosing hemangiomas of the lung. Arch Pathol Lab Med 2012;136:1580-1584.
46. Ballard M, Sangoi A, McKenney JK, et al. Napsin A staining in adrenal cortical neoplasms. Arch Pathol Lab Med 2013;137:883.
47. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol 2008;129:592-605.
48. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol 2001;20:155-159.
49. Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of 'Napsin-A' in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol 2013;21:191-195.